SereNeuro's SN101 'Pain Sponge' Therapy Shows Promise for Non-Opioid Osteoarthritis Treatment
Key Insights
SereNeuro Therapeutics (search) presented preclinical data at ISSCR showing SN101 (search), a first-in-class iPSC-derived therapy that uses mature pain-sensing neurons to sequester inflammatory factors and relieve chronic osteoarthritis (search) pain.
The novel "pain sponge" approach positions SN101 (search) as a potential disease-modifying osteoarthritis (search) drug (DMOAD) that halts cartilage degradation while providing non-addictive pain relief.
SN101 (search) differs from conventional treatments by using fully mature, non-dividing cells that express all canonical pain receptors (search), enabling simultaneous modulation of multiple pain pathways without opioid addiction risks.
SereNeuro Therapeutics (search) unveiled promising preclinical data for SN101 (search), a first-in-class induced pluripotent stem cell (iPSC)-derived therapy that takes a counterintuitive approach to chronic pain (search) management. Presented at the International Society for Stem Cell Research (ISSCR) Symposium in Cambridge, Massachusetts, the data demonstrates how mature pain-sensing neurons can be repurposed as therapeutic agents to treat osteoarthritis (search) pain while preserving joint tissue.
Revolutionary "Pain Sponge" Mechanism
SN101 (search) challenges conventional pain management strategies by utilizing mature, iPSC-derived peripheral pain-sensing neurons (nociceptors (search)) as therapeutic tools rather than targets. "Our approach utilizes high-purity, iPSC-derived nociceptors that effectively function as a sponge for pain factors," said Gabsang Lee, PhD, scientific co-founder of SereNeuro and professor of neurology and neuroscience at Johns Hopkins University. "By injecting SN101 cells, we relieve pain and halt cartilage degradation."
Rather than transmitting pain signals to the brain, SN101 (search) cells sequester inflammatory pain mediators locally within the joint. The cells also secrete mechanistically validated regenerative factors, creating an environment that supports healthier cartilage and bone remodeling. This positions SN101 as a potential disease-modifying osteoarthritis (search) drug (DMOAD)—a meaningful advancement over today's symptom-focused and often degenerative pain treatments.
Advantages Over Current Therapies
The ISSCR presentation highlighted several ways SN101 (search) stands apart from both emerging and established pain treatments. Unlike ion channel inhibitors that block one pathway, SN101 cells naturally express all canonical pain receptors (search) and ion channels (search), enabling simultaneous modulation of multiple pain and inflammation signals.
The therapy also offers an alternative to corticosteroids (search), which may provide temporary relief but are associated with accelerated cartilage degeneration over time. "Current standard-of-care treatments may worsen joint health in the long run," said Daniël Saris, MD, PhD, professor of orthopedics and regenerative medicine at Mayo Clinic and member of SereNeuro's Clinical Advisory Board. "SN101 (search) creates an environment that preserves joint tissue while relieving chronic pain (search)—without addiction risk."
Enhanced Safety Profile and Clinical Potential
Key highlights from the ISSCR data presentation include an improved safety profile through the use of fully mature, non-dividing cells, which reduces tumorigenicity risks associated with proliferative cell therapies. The approach offers non-addictive pain management as a biological alternative to opioids (search), addressing an urgent need for safer chronic pain (search) solutions. Preclinical data indicates disease-modifying potential with halted cartilage degradation and promotion of healthy bone remodeling.
Maryland-Based Innovation
SereNeuro's scientific foundation is closely tied to Baltimore's academic and biomedical research community, particularly through Johns Hopkins University. Co-founder and CEO Daniel Saragnese has guided multiple therapeutic candidates from preclinical stages through clinical development at venture-backed spin-outs from Stanford and Johns Hopkins University, including Earli ($40M Series A), Ashvattha ($69M Series B), and Graybug Vision (NASDAQ: GRAY).
In 2025, SereNeuro Therapeutics (search) received a Commercialization Grant from the Maryland Stem Cell Research Fund (search) (MSCRF), a program administered by the Maryland Technology Development Corporation (TEDCO). The MSCRF program is designed to help translate promising stem cell discoveries toward clinical and commercial readiness, reinforcing Maryland's role as a national hub for regenerative medicine and cell therapy development.
Path to Clinical Development
SereNeuro is advancing SN101 (search) toward IND-enabling studies as part of a broader pipeline focused on chronic and neuropathic pain (search) conditions. As the biotech industry continues to seek durable, non-opioid solutions, SN101 represents a convergence of stem cell biology, neuroscience, and regenerative medicine—areas where Maryland institutions and funding programs have played a sustained leadership role.